BackArno Therapeutics Overview
Arno Therapeutics, Inc.

Arno Therapeutics Return on Equity

Valuation check: ARNI's ROE is 240.41%, above the Healthcare sector average of -100.59%.

Get informed when a big investor buys or sells

+ Follow

ROE

240.41%

Return on Equity

240.41%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Arno Therapeutics (ARNI) FAQ

As of the most recent data, ARNI shows a ROE of 240.41%. That is above the Healthcare sector average of -100.59%. Scroll down for historical charts and peer comparison views.

The Healthcare sector average ROE is about -100.59%. Arno Therapeutics is at 240.41%, which is higher that average. That is roughly 339.0% above the sector mean. Use the comparison chart on this page to see how ARNI stacks up against individual peers as well.

Check the historical chart to see whether ARNI's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Arno Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Arno Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 240.41%) with ownership activity and broader fundamentals.

The Healthcare average ROE is about -100.59%, while ARNI is at 240.41%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.